Estimaciones de analistas de Wall Street para Molecular Partners AG (MOLN): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-29 | $-0.46 | ||
| 2026-08-25 | $-0.44 | $-0.45 | +2.2% |
| 2026-05-12 | $-0.45 | $-0.38 | -18.4% |
| 2026-03-12 | $-0.41 | $-0.40 | -2.5% |
| 2025-10-30 | $-0.41 | $-0.46 | +10.9% |
| 2025-08-25 | $-0.67 | $-0.53 | -26.4% |
| 2025-05-15 | $-0.50 | $-0.42 | -18.6% |
| 2025-03-06 | $-0.34 | $-0.44 | +22.7% |
Ratios de valoración
| Precio / Valor contable | 2.08 |
| EV / EBITDA | -1.34 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $23.0M | $20.0M | $10.4M | $20.4M | $9.3M | $9.3M | $189.6M | $7.0M | $5.0M | 0 |
| Coste de Ventas | $14.6M | $17.8M | $15.6M | $43.5M | $56.1M | $55.7M | $50.7M | $47.8M | $47.5M | $2.0M |
| Beneficio Bruto | $8.5M | $2.2M | -$5.2M | -$23.1M | -$46.7M | -$46.4M | $138.8M | -$40.8M | -$42.5M | -$2.0M |
| I+D | $35.2M | $37.5M | $38.2M | $43.5M | $56.1M | $55.7M | $50.7M | $48.8M | $48.6M | $40.2M |
| Generales y Administrativos | $7.2M | $8.3M | $9.5M | $13.2M | $11.0M | $16.9M | $21.8M | $19.0M | $17.2M | $14.9M |
| Gastos Operativos | $42.5M | $45.9M | $47.8M | $57.0M | $67.7M | $72.7M | $72.9M | $20.3M | $18.7M | $50.9M |
| Beneficio Operativo | -$19.5M | -$25.8M | -$37.4M | -$36.7M | -$58.3M | -$63.4M | $116.6M | -$61.1M | -$61.2M | -$58.1M |
| EBITDA | -$17.5M | -$24.7M | -$36.1M | -$33.7M | -$59.6M | -$60.7M | $119.0M | -$59.5M | -$51.6M | -$59.5M |
| Gastos por Intereses | $89000 | $197000 | $102000 | $100625 | $323881 | $608137 | $648123 | $49000 | $25000 | $18000 |
| Beneficio Antes de Impuestos | -$18.6M | -$25.4M | -$37.0M | -$36.3M | -$62.8M | -$63.8M | $117.9M | -$62.0M | -$54.0M | -$61.6M |
| Impuestos | 0 | -$1000 | -$156000 | $17000 | -$11000 | $2000 | 0 | 0 | $2000 | $2000 |
| Beneficio Neto | -$18.6M | -$25.4M | -$37.0M | -$36.3M | -$62.8M | -$63.8M | $117.9M | -$62.0M | -$54.0M | -$61.7M |
| BPA | $-0.91 | $-1.22 | $-1.75 | $-1.69 | $-2.51 | $-2.06 | $3.63 | $-1.89 | $-1.59 | $-1.65 |
| BPA Diluido | $-0.91 | $-1.22 | $-1.75 | $-1.69 | $-2.51 | $-2.06 | $3.54 | $-1.89 | $-1.59 | $-1.65 |
| Acciones en Circulación (Diluidas) | $20.4M | $20.9M | $21.2M | $21.4M | $25.0M | $31.0M | $33.3M | $32.8M | $34.0M | $37.3M |
Precio
| Precio | $3.92 |
| Capitalización | $147M |
| Bolsa | NASDAQ |
| País | CH |
Empresas relacionadas: ALEC · APLT · CRBP · CRDF · ELTX · MIST · NKTX
Explorar sector: Healthcare · Biotechnology
Más secciones de MOLN: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones